# FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression

> clinical trial · VERIFIED · 2026-07-09

Status: NOT_YET_RECRUITING · Sponsor: Boehringer Ingelheim · Condition: Interstitial Lung Diseases

- Company: Boehringer Ingelheim
- Sector: Interstitial Lung Diseases
- Primary source: https://clinicaltrials.gov/study/NCT07540988

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.